CDMRP Duchenne Muscular Dystrophy Research Program: Clinical\ Translational Research Award

The vision of the FY24 DMDRP is to preserve and improve the function and quality of life, and to extend the life span of all individuals with DMD.

To meet the intent of the funding opportunity, all applications for the FY24 DMDRP Clinical/Translational Research Award (CTRA) must address at least one of the following Focus Areas:

Preclinical Translational Research

• Extension or expansion of existing preclinical data in support of Investigational New Drug (IND) application-enabling studies.

Clinical Research

• Clinical studies designed to improve care and quality of life

• Prospective real-world data collection for combination or sequential therapies, and/or followup safety and efficacy studies

• Assessment of clinical trial tools and outcome measures

• Natural history studies in understudied systems

The FY24 DMDRP CTRA offers two funding levels 

• Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/application’s direct costs budgeted for the entire period of performance should not exceed $650,000.

• Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/application’s direct costs budgeted for the entire period of performance should not exceed $1.35M

It is expected that three (3) awards will be granted. 

Funding: Funding level 1: $650,000 total; Funding level 2: $1,350,000 total.  
Duration: Funding level 1- 3 years; Funding level 2- 4 years 

Research Authority due date: 25.7.24
Pre application (required) due date: 1.8.24
Full application due date: 22.8.24